Adocia Announces Oral Presentation Reviewing M1Pram (ADO09) at the 57th Annual Meeting of the European Association for the Study of Diabetes (EASD)

·4 min read

LYON, France, September 21, 2021--(BUSINESS WIRE)--Regulatory News:

Adocia (Euronext Paris: FR0011184241 – ADOC) (Paris:ADOC), a clinical-stage biopharmaceutical company focused on the treatment of diabetes and other metabolic diseases with innovative formulations of proteins and peptides, announced today that it will deliver an oral presentation covering proprietary M1Pram (ADO09) pramlintide insulin at the 57th Annual Meeting of the European Association for the Study of Diabetes (EASD), being held virtually during September 27th – October 1st, 2021.

On this occasion, Adocia will be presenting Parts A and B of the Proof-of-Concept Phase I clinical trial with M1Pram, a co-formulation of pramlintide and insulin A21G that improves post-prandial glucose and body weight versus insulin aspart in type 1 diabetes.

Date: September 29th, 2021
Hour: from 1:30pm until 3:00pm CEST
Session: OP 23 Advances in insulin therapy
Title: "Ado09, a co-formulation of pramlintide and insulin A21G improves post-prandial glucose and body weight versus insulin aspart in type 1 diabetes"
Website: https://www.easd.org/
Programme: https://www.easd.org/annual-meeting/easd-2021.html#section-scientific-programme

About the EASD Annual Meeting

The EASD Annual Meeting is one of the biggest European meetings dedicated to the latest developments and insights in diabetology. The meeting attracts key opinion leaders, company executives, scientists, physicians, researchers, nurses and students interested in diabetes and related subjects. The goal of the EASD Annual Meeting is to encourage excellence in diabetes care through advances in research and education.

About Adocia

Adocia is a clinical-stage biotechnology company that specializes in the development of innovative formulations of therapeutic proteins and peptides for the treatment of diabetes and metabolic diseases. In the diabetes field, Adocia’s portfolio of injectable treatments is among the largest and most differentiated of the industry, featuring six clinical-stage products and several pre-clinical products. The proprietary BioChaperone® technological platform is designed to enhance the effectiveness and/or safety of therapeutic proteins while making them easier for patients to use. Adocia customizes BioChaperone® to each protein for a given application.
Adocia’s clinical pipeline includes five novel insulin formulations for the treatment of diabetes: two ultra-rapid formulations of insulin analog lispro (BioChaperone® Lispro U100 and U200), a combination of basal insulin glargine and rapid acting insulin lispro (BioChaperone® Combo) and two combinations of a prandial insulin with amylin analog pramlintide (M1Pram and BioChaperone® LisPram). The clinical pipeline also includes an aqueous formulation of human glucagon (BioChaperone® Glucagon) for the treatment of hypoglycemia.
Adocia preclinical pipeline includes bi-hormonal combinations for diabetes treatment: a combination of rapid acting insulin analogs and pramlintide (BioChaperone® AsPram), a combination of insulin glargine with GLP-1 receptor agonists (BioChaperone® Glargine Liraglutide). In addition, there are three multi-hormonal products for the treatment of obesity: a combination of glucagon and exenatide (BioChaperone® GluExe), a combination of pramlintide and exenatide (PramExe) and a triple combination of pramlintide glucagon exenatide (BC PramGluExe).
Adocia recently added a preclinical program to its pipeline with a cell therapy initiative focused on the development of a hydrogel scaffold for use in people with type 1 diabetes. The first patent application supporting this program has been filed.

Disclaimer

This press release contains certain forward-looking statements concerning Adocia and its business. Such forward-looking statements are based on assumptions that Adocia considers as being reasonable. However, there can be no guarantee that the estimates contained in such forward-looking statements will be achieved, as such estimates are subject to numerous risks including those which are set forth in the "Risk Factors" section of the Universal Registration Document that was filed with the French Autorité des marchés financiers on April 20, 2021 (a copy of which is available at www.adocia.com), in particular uncertainties that are linked to research and development, future clinical data, analyses, and the evolution of the economic context, the financial markets and the markets in which Adocia operates.
The forward-looking statements contained in this press release are also subject to risks not yet known to Adocia or not considered as material by Adocia as of this day. The occurrence of all or part of such risks could cause that actual results, financial conditions, performances, or achievements of Adocia be materially different from those mentioned in the forward-looking statements.
This press release and the information contained herein do not constitute an offer to sell or the solicitation of an offer to buy Adocia’s shares in any jurisdiction.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210921005808/en/

Contacts

Adocia
Gérard Soula
CEO
contactinvestisseurs@adocia.com
Ph: +33 4 72 610 610
www.adocia.com

MC Services AG
Adocia Press Relations Europe
Raimund Gabriel
Managing Partner
adocia@mc-services.eu
Ph: +49 89 210 228 0

The Ruth Group
Adocia Investor Relations USA
Brett Mermelstein
Senior Account Executive
bmermelstein@theruthgroup.com
Ph.: +1 267 639 0721

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting